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Abstract
Background: Tobacco smoking is a major risk factor for several oral diseases, including periodontitis, and electronic
cigarettes (e-cigarettes) are increasingly being used for smoking cessation. This study aimed to assess the viability of
delivering and evaluating an e-cigarette intervention for smoking cessation within the dental setting, prior to a
definitive study.
Methods: A feasibility study, comprising a pilot randomised controlled trial and qualitative process evaluation,
was conducted over 22 months in the Newcastle upon Tyne Hospitals NHS Dental Clinical Research Facility, UK.
The pilot trial comprised a two-armed, parallel group, individually randomised, controlled trial, with 1:1 allocation.
Participant eligibility criteria included being a tobacco smoker, having periodontitis and not currently using an
e-cigarette. All participants received standard non-surgical periodontal therapies and brief smoking cessation
advice. The intervention group additionally received an e-cigarette starter kit with brief training. Proposed outcomes
for a future definitive trial, in terms of smoking behaviour and periodontal/oral health, were collected over 6 months
to assess data yield and quality and estimates of parameters. Analyses were descriptive, with 95% confidence intervals
presented, where appropriate.
Results: Eighty participants were successfully recruited from a range of dental settings. Participant retention was 73%
(n = 58; 95% CI 62–81%) at 6 months. The e-cigarette intervention was well received, with usage rates of 90% (n = 36;
95% CI 77–96%) at quit date. Twenty percent (n = 8; 95% CI 11–35%) of participants in the control group used an
e-cigarette at some point during the study (against advice). The majority of the outcome measures were
successfully collected, apart from a weekly smoking questionnaire (only 30% of participants achieved ≥ 80%
completion). Reductions in expired air carbon monoxide over 6 months of 6 ppm (95% CI 1–10 ppm) and 12 ppm (95%
CI 8–16 ppm) were observed in the control and intervention groups, respectively. Rates of abstinence (carbon
monoxide-verified continuous abstinence for 6 months) for the two groups were 5% (n = 2; 95% CI 1–17%; control
group) and 15% (n = 6; 95% CI 7–29%; intervention group).
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Conclusions: Data suggest that a definitive trial is feasible and that the intervention may improve smoking quit rates.
Insights were gained into how best to conduct the definitive trial and estimates of parameters to inform design
were obtained.
Trial registration: ISRCTN, ISRCTN17731903; registered 19 September 2016 http://www.isrctn.com/ISRCTN17731903.
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Background
Periodontal diseases are amongst the most common
inflammatory conditions in humans [1]. Periodontitis, an
advanced form of periodontal disease, has a multifacto-
rial aetiology, but the principal process involves a dental
plaque biofilm accumulating in the subgingival environ-
ment, causing an immune and inflammatory response
that leads to destruction of the tooth supporting struc-
tures. Consequences of periodontal disease progression
include tooth mobility and eventually tooth loss. Severe
periodontitis, threatening tooth retention, affects ap-
proximately 10% of UK adults, with moderate periodon-
titis affecting 40–60% [2]. A recent estimate is that 4.4
million adults in the UK may have severe disease [3].
There are multiple risk factors for periodontal diseases,
but tobacco smoking is one of the most important [4].
Smoking is thought to affect the periodontal tissues via
multiple pathways, including effects on the host immune
and inflammatory response, impaired blood flow and
microbiological changes [5]. Of particular relevance in the
management of periodontitis is the knowledge that
smokers who quit are 30% more likely to see clinically
significant improvements than individuals who continue
to smoke [6]. Smoking cessation advice (SCA) is therefore
a critical component of periodontal therapy, and usual
care involves a brief advice intervention, e.g. the ‘3 A’s’
technique: Ask, Advise, Act [7, 8].
The recent development of electronic cigarettes (e-ciga-
rettes) has introduced a new option for smokers who wish
to attempt quitting. Although still limited, there is a grow-
ing body of evidence to suggest that e-cigarettes are a
useful smoking cessation aid [9]. The risks associated with
using e-cigarettes appear to be much lower than those of
tobacco cigarettes with several government and pro-
fessional bodies estimating the health risks to be less than
5% of those associated with tobacco smoking [10, 11]. At
a population level, e-cigarettes have been popular
with 2.8 million users in the UK as of 2017 [12].
Research is required to determine the effectiveness of
e-cigarettes as a smoking cessation or reduction tool
within the dental setting and any subsequent impacts on
oral health, specifically with regard to the periodontal
tissues and periodontal treatment outcomes. An essential
pre-requisite to a definitive trial of the effectiveness and
cost-effectiveness of e-cigarettes in this context is a well-
designed pilot trial to reduce the uncertainties inherent in
the introduction and evaluation of a new technology. The
aims of this feasibility study and pilot trial were to assess
eligibility, recruitment and retention rates; to explore the
feasibility and acceptability of the intervention and of
trial procedures; and to collect data to inform power
calculations for the definitive trial.
Methods
Study design and setting
This feasibility study included a single-centre, two-arm,
parallel group, individually randomised controlled pilot
trial (pilot RCT), with 1:1 allocation, conducted in a
dental clinical research facility (DCRF), located in the
Newcastle Dental Hospital (NDH), part of the Newcastle
upon Tyne Hospitals NHS Foundation Trust, Newcastle
upon Tyne, UK. The participants were smokers who had
a diagnosis of periodontitis and who were provided with a
smoking cessation intervention alongside their standard
periodontal therapy. Participants in the control group
received usual care (SCA), and those in the intervention
group received usual care plus an offer of an e-cigarette
starter kit.
A favourable ethical opinion was obtained from the
North East-Tyne & Wear South NHS Research Ethics
Committee (16/NE/0219), and the trial was prospec-
tively registered (ISRCTN17731903). The study ad-
hered to the Consolidating Standards of Reporting
Trials (CONSORT) guidance for pilot and feasibility
trials [13] (see Additional file 1 for the completed
CONSORT checklist). Protocol amendments with reasons
are detailed in Additional file 2.
Identification and recruitment
Potential participants were identified through two
routes: at new patient and treatment clinics of the NDH
or by primary care practitioners (general dental prac-
titioners, therapists, hygienists) working in the north
east England region. Table 1 details the participant
eligibility criteria. Potential participants were identified
by a member of the existing clinical care team. Where
possible (in the NDH), a member of the research team
attended the clinic to discuss the study with the patient,
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provide the participant information sheet and arrange
study appointments. If required, a screening visit was
arranged in the DCRF to check for participant eligibility
and answer any further questions. Primary care prac-
titioners in participant identification centres (PICs)
who identified potentially eligible patients were asked
to provide the patient with a participant information
sheet and refer them directly to the DCRF.
Randomisation
Following assessment of eligibility and completion of
written informed consent, participants were randomised
to the control or intervention group, in a 1:1 ratio using
random permuted blocks of variable size (2, 4 or 6). The
allocation schedule was generated by a statistician with
no other involvement in the study, and randomisation
was performed using a secure password-protected
web-based system. There were no stratification factors.
Sample size
No formal sample size calculation was performed for
this pilot RCT. In line with recommendations for pilot
trials [14], our target was to achieve at least 30 patients
retained in each arm of the trial. Based on prior ex-
perience, we anticipated an attrition rate of 25% and
therefore aimed to randomise 40 participants to each
arm of the study, 80 in total.
Interventions
All participants in this study received SCA delivered by
a single treating dentist (RH) alongside their dental and
periodontal treatment, as part of usual care. This SCA
followed the ‘3 A’s’ (Ask, Advise, Act) technique [8]. A
referral to the ‘Newcastle Stop Smoking’ services was
available to all participants. The SCA intervention was
audio-recorded to allow tests for fidelity and is fully
described in Additional file 3.
Participants in the intervention group were also
offered an e-cigarette starter kit (as detailed in
Additional file 4). The participants were provided with an
approximately 2-week supply of e-liquid (with a choice of
flavour and nicotine strength) and information on where
to buy more. The e-cigarette intervention is fully
described in Additional file 5.
All participants received standard non-surgical
periodontal therapy. Oral hygiene instruction (detailed
in Additional file 6) and full-mouth debridement were
provided in line with local and international guidance
on an individualised basis [15].
Concomitant care
Participants in the control group were asked to commit
to not using an e-cigarette for the duration of the study,
especially during the first 4 weeks, and were invited to
sign a commitment form agreeing to this. Participants in
the intervention group were advised to use only the
recommended brand of e-liquids for the duration of
the study.
Outcomes and data collection methods
Feasibility outcome measures included rates of eligibility,
recruitment and retention; intervention acceptability;
randomisation group cross-over rates; and the provision
Table 1 Eligibility criteria
Inclusion criteria
Aged over 18 years old
Smoker of burnt tobacco (≥10 factory-made cigarettes/day or 7 g
[0.25 oz]) loose tobacco/day or 14 hand-rolled cigarettes/day)
Not currently using an e-cigarette, or not having used one for more
than 2 days in the last 30 days
Willing and able to come to the DCRF for the required study visits
Having a minimum of 16 natural teeth (excluding third molars)
Being diagnosed with periodontitis, having interproximal pocket
probing depths (PPDs) of ≥ 5 mm at ≥ 8 sites
Exclusion criteria
Having used an e-cigarette for more than 2 days in the last 30 days
Infectious or systemic diseases (myocardial infarction, cerebrovascular
accident; phaeochromocytoma; uncontrolled hyperthyroidism; liver or
kidney problems; chronic obstructive pulmonary disease) that may be
unduly affected by participation in this study
Haemodynamically unstable patients hospitalised with severe
arrhythmias
Patients taking the medication adenosine (due to drug interaction risk)
Lack of capacity to be able to consent to the research project and/or
inability to follow study instructions
Participation in a dental research study within the previous 20 days
Pregnant by medical history, or nursing
Received any non-surgical periodontal therapy other than a routine
scale and polish in the last 6 months
Currently undergoing or requiring extensive dental, orthodontic or
implant treatment, or treatment for peri-implantitis
Clinical characteristics requiring further discussion with potential
participants
Asthma (severity needed to be assessed, patient made aware that
nicotine replacement therapy (NRT) is better than smoking but best
to use NRT as a short-term stop smoking treatment)
Long-term throat disease (severity needs to be assessed, NRT use may
exacerbate symptoms)
Stomach ulcer, duodenal ulcer, irritation or inflammation of the
stomach or throat (NRT may exacerbate symptoms)
Diabetes mellitus (advised to monitor their blood glucose more
closely when initiating treatment, advised to discuss this with their
doctor or diabetic nurse specialist)
Those taking theophylline, clozapine and ropinirole medications
(metabolised by CYP 1A2 and with a narrow therapeutic
window, can be affected by stopping smoking, advised to see
their doctor to discuss changing the dose prior to starting the
quit attempt).
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of data on smoking and oral health outcomes being
rehearsed for the future definitive trial. The smoking
behaviour outcomes comprised self-reported tobacco and
e-cigarette use, expired air carbon monoxide (eCO),
salivary cotinine (SC), salivary anabasine (SA), Fagerstrom
Test for Nicotine Dependence (FTND) [16] and Mood
and Physical Symptoms Scale (MPSS) [17]. Rates of
continuous eCO-verified smoking abstinence at 6 months
were calculated following the Russell Standard (RS6) [18].
The oral health outcomes comprised pocket probing
depth (PPD), Modified Gingival Index (MGI) [19], plaque
index (PI) [20], clinical attachment level (CAL), bleeding
on probing (BOP), clinical oral dryness score (CODS)
[21], periodontal epithelial surface area (PESA) [22],
Periodontal Inflamed Surface Area (PISA) [22] and
the UK Oral Health-related Quality of Life measure
(OHQoL-UK) [23]. The data collection method for each
outcome is described in Additional file 7. Adverse events
were monitored at each study visit.
Blinding
Due to the nature of this study, the participants and
treating clinicians could not be blinded to the assigned
intervention. However, the oral health indices were
collected by a single, trained, calibrated research hygienist
who was blinded to the assigned intervention. Participants
were asked not to disclose their smoking status or
methods of smoking cessation during the assessment
appointments.
Study visits and follow-up
Participants were asked to attend for six study visits over
6 months. There were no additional visits for research pur-
poses with all visits being in line with normal periodontal
therapy and follow-up. Randomisation, smoking cessation
interventions and baseline measurements/sample collec-
tion were delivered at visit 1. Visit 1 was delivered in two
parts. First, a dentist confirmed eligibility, obtained written
consent, collected baseline smoking-related outcome
measures and OHQoL-UK, randomised participants and
provided the appropriate smoking cessation intervention.
Second, participants were seen by a research hygienist,
blinded to treatment allocation and smoking status, who
collected the remaining clinical measurements. The initial
periodontal treatment was delivered over visits 2 and 3.
Visit 2 was designated as the target quit date and was
arranged after discussion with the participant with the
recommendation that it was ideally within 4 weeks of
visit 1 (the actual duration varied between 0 and 9
weeks with a mean [SD] of 2.6 [2.0] weeks). Three
follow-up visits with data collection and supportive
periodontal therapy were conducted at 4 weeks (visit 4),
3 months (visit 5) and 6 months (visit 6) post-quit date
(visit 2). A weekly smoking status online or paper
questionnaire was distributed for the duration of the
study, depending on participant preference. The online
version was distributed weekly, and the paper version was
distributed and completed at each study visit. A schedule
of events is provided in Additional file 8.
Collection and analysis of biological samples
Saliva was collected at each study visit (excluding visit 3).
Gingival crevicular fluid (GCF) and subgingival plaque
samples were collected prior to recording periodontal
indices at visits 1, 5 and 6 (this pilot RCT will report on
the ability to collect these samples rather than their
analysis, which will be reported elsewhere).
Data collection and analysis for the process evaluation
One-to-one semi-structured interviews were conducted
with a purposive sample of 28 participants, 14 of whom
received the e-cigarette intervention and the remainder
of whom received the control condition (dentist-deli-
vered SCA). Participants were sampled to reflect a range
of ages and smoking behaviours. An initial interview was
conducted shortly after the SCA intervention (usually at
visit 3) with a follow-up interview approximately 6 months
later (usually at visit 6). Interviews were audio-recorded,
anonymised and transcribed verbatim. Transcripts were
analysed thematically.
Data analysis for the pilot RCT
Analyses were performed according to a predefined statis-
tical analysis plan (Additional file 9). In accordance with
recommendations for the analysis of pilot and feasibility
studies, the data analyses were descriptive, and statistical
comparisons between the randomised groups were not
undertaken. For the feasibility outcome measures, all pro-
portions/rates were reported with 95% confidence inter-
vals (CIs). Quantitative outcome measures were reported
as means and standard deviations with 95% CIs.
Participants with missing smoking outcome data
(e.g. those not attending for review) were considered
as continuing smokers or to have resumed smoking, in
line with standard research practice [9, 18]. For conti-
nuous data (eCO, SC, SA), missing data were not imputed.
Missing periodontal data due to participant loss to
follow-up were not imputed. For teeth that were lost or
extracted during the study period, a ‘last observation
carried forward’ approach was used for the periodontal
indices where possible, i.e. if a tooth was lost between visit
5 and 6, then the periodontal data were carried forwards
from visit 5. If a tooth was lost before visit 5, then no data
were imputed. For missing FTND and MPSS question-
naire data, the ‘rule of halves’ was employed [24–26].
For missing OHQoL-UK questionnaire data, patients
who had not responded to ≥ 10% of the items in
OHQoL-UK questionnaire were excluded from analyses,
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with their responses being treated as missing data. For
patients who had < 10% missing responses, values for the
missing items were derived using group mean score
imputation for each item in order to calculate the indivi-
dual domain scores and the summary scores as reported
previously [27–29]. Data were analysed in SPSS (IBM
SPSS Statistics, Version 24, Chicago, SPSS Inc.).
Results
One hundred and nineteen potentially eligible participants
were identified over the 15-month recruitment period
(20/09/2016–07/12/2017). Of these, 80 were found to be
eligible and enrolled in the study. Participants were
recruited from a range of sources (see Additional file 10).
Screening data were only available for one recruitment
source (NDH periodontal new patient clinic), from
which the eligibility rate (number eligible/number
screened) was estimated to be 7.4% (29/391, 95% CI
5.2–10.5%) [complete eligibility outcomes are pre-
sented in Additional file 11]. Data collection was com-
pleted on 7 June 2018, when the last patient visit occurred.
Figure 1 shows the CONSORT flow diagram.
Participant baseline characteristics
The study sample comprised 38 (47.5%) males and 42
(52.5%) females (Table 2). Ethnicity was primarily white
(n = 75, 94%) (British, Irish or other white) with five (6%)
Asian or Asian British, reflective of the North East’s
population [30]. The majority of the participants were in
employment (n = 60, 75%), mainly working in routine or
manual (n = 20, 25%) or intermediate (n = 22, 27.5%)
occupations. The mean age of the participants at ran-
domisation was 44.3 years, ranging from 19 to 71 years.
The mean number of cigarettes smoked per day was
17.4. The majority of participants reported started
smoking in their teenage years, with a mean age of 16
years. The mean baseline eCO reading was 20.6 ppm.
The participants had a moderate nicotine dependence
with a mean FTND score at baseline of 5.0. The number
of teeth (excluding third molars) that participants had at
baseline ranged from 16 to 28, with a mean of 23.9. The
participants demonstrated a severe level of periodontal
disease, in keeping with the study inclusion criteria. The
mean PPD was 4.0mm with the mean percentage of sites
with PPDs ≥ 5mm being 40%. The mean percentage BOP
was 20%. A low-moderate amount of xerostomia was
observed with a mean CODS of 4.0, indicating some
reduced mucosal wetness.
There was good balance with respect to sex, age, eth-
nicity, occupation and smoking behaviour demographics
across the groups (Table 2). Most of the oral health
outcomes were approximately balanced across rando-
misation groups, although it was noted that percentage
sites with PPD ≥ 5 mm, PI, BOP and PISA (which are
associated with the severity of periodontitis) were slightly
higher on average in the control group (Table 2).
Participant follow-up
Four participants withdrew from the study, and 18 were
lost to follow-up. The most frequent time point for
withdrawal/loss to follow-up was after visit 3 (second and
final treatment visit). There were no differences in the
numbers of participants attending each visit by random-
isation group and only minor differences in the proportion
attending within the designated visit window (see
Additional file 12). At the final data collection point
(visit 6, 6 months), 11 participants in each randomisation
group did not attend, giving 58 participants for the final
analysis. Those participants lost to follow-up appeared to
have higher eCO and FTND readings and more severe
periodontal diseases at baseline (see Additional file 13).
Safety data
There were no serious adverse events (SAEs). However,
56 adverse events (AEs) were reported in 35 participants.
The most frequently reported AEs were toothache,
dentine hypersensitivity, tooth/teeth loss, dental/peri-
odontal abscess and fractured/carious filling or tooth
(Table 3). Seven participants had unplanned tooth
extractions during the study period, losing a total of 15
teeth between them. Two participants reported mouth
ulceration, and three separate participants reported sore-
ness of the intra-oral soft tissues. These five participants
were in the intervention group, and the symptoms could
be related to the e-cigarette intervention (other forms of
orally administered NRT have been associated with sore-
ness and ulceration) or could be the result of the higher
quit rate in the intervention group (smoking cessation is
also associated with soreness and ulceration).
Participant compliance
Participant compliance with attending review visits
(visits 4, 5, 6) was similar across randomisation group, but
differences were present across recruitment source (see
Additional file 14). Participant compliance with comple-
ting the weekly smoking status questionnaire was poor,
with only 46% of participants completing the question-
naire at least half of the time (> 14 entries) and 30% com-
pleting it at least 80% of the time (> 23 entries), increasing
to 64% and 41% respectively, for those 58 participants
who completed the study (see Additional file 15).
Intervention usage
One participant in the intervention group declined the
starter kit on the grounds that he did not intend to change
his smoking behaviour (intention to quit was not an
inclusion criterion for this study). Acceptability of the
e-cigarette intervention was high, with 90% of participants
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using the device at the quit date (visit 2). The most
popular initial e-liquid flavour combination was to-
bacco and mint followed by mint alone. Over half of
participants (52%) did not include a tobacco flavour in
their initial selection, while 62% included mint flavour
(see Additional file 16). The most frequently selected
nicotine strengths were 12mg/ml and 18mg/ml, selected
by over half of participants, while none opted for the
lowest concentration option (see Additional file 17). The
proportion of participants still using the device remained
high (> 70%) at both the 4-week (visit 4) and 3-month
(visit 5) reviews. By the end of the study, approximately
half of the participants in the intervention group were still
using the e-cigarette, increasing to 72% for those 29 who
completed the study (see Additional file 18). Based on
self-reporting of those who attended all visits, the mean
Fig. 1 CONSORT flow diagram. NDH PC = Newcastle Dental Hospital (NDH) periodontal new patient clinic, DEC = dental emergency clinic (at
NDH), PIC = participant identifying centre (primary care), FTA = failed to attend
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Table 2 Participant baseline characteristics
Control group n = 40 Intervention group n = 40 Total n = 80
Sex, n (%)
Female 20 (50%) 22 (55%) 42 (52.5%)
Male 20 (50%) 18 (45%) 38 (47.5%)
Ethnicity, n (%)
White (British, Irish, other White) 36 (90%) 39 (97.5%) 75 (93.8%)
Asian or Asian British (Indian, Pakistani, Bangladeshi, other Asian) 4 (10%) 1 (2.5%) 5 (6.3%)
Occupation, n (%)
Working in a routine or manual occupation 9 (22.5%) 11 (27.5%) 20 (25%)
Working in an intermediate occupation 9 (22.5%) 13 (32.5%) 22 (27.5%)
Working in a managerial or professional occupation 9 (22.5%) 9 (22.5%) 18 (22.5%)
Unemployed/not working for a year or more 6 (15%) 2 (5%) 8 (10%)
Full-time student 0 1 (2.5%) 1 (1.3%)
Retired 1 (2.5%) 4 (10%) 5 (6.3%)
Sick/disabled/unable to return to work 4 (10%) 0 4 (5.0%)
Home carer (unpaid) 2 (5%) 0 2 (2.5%)
Age (years), mean (SD) 44.6 (9.5) 44.0 (11.8) 44.3 (10.7)
Number of cigarettes/day (any), mean (SD) 17.5 (6.9) 17.4 (6.4) 17.4 (6.6)
Number of factory cigarettes/day, mean (SD) 16.6 (7.2), n = 33 14.8 (4.4), n = 26 15.8 (6.1), n = 59
Number of hand-rolled cigarettes/day, mean (SD) 19.0 (7.1), n = 8 22.1 (7.0), n = 14 21.0 (7.0), n = 22
Age started smoking, mean (SD) 16.0 (2.8) 15.3 (3.2) 15.7 (3.0)
eCO (ppm), mean (SD) 18.1 (10.0) 23.0 (12.2) 20.6 (11.3)
FTND, mean (SD) 5.0 (2.4) 5.0 (1.8) 5.0 (2.1)
MPSS, mean (SD) 22.8 (7.0) 22.8 (5.9) 22.8 (6.4)
SC (ng/ml), mean (SD) 303.4 (128.3) 342.6 (138.1) 323.5 (134.0)
SA (ng/ml), mean (SD) 1.1 (1.4) 1.2 (1.2) 1.2 (1.3)
Number of teeth (excluding 3rd molars), mean (SD) 24.0 (3.6) 23.8 (4.0) 23.9 (3.8)
Mean PI, mean (SD) 1.1 (0.7) 0.8 (0.6) 1.0 (0.7)
% BOP score, mean (SD) 23.9 (18.3) 16.5 (13.4) 20 (16.4)
Mean MGI, mean (SD) 2.5 (0.5) 2.5 (0.4) 2.5 (0.5)
Mean PPD (mm), mean (SD) 4.1 (0.8) 3.9 (0.7) 4.0 (0.7)
Mean CAL (mm), mean (SD) 5.2 (1.4) 5.1 (1.3) 5.1 (1.3)
PESA (mm2), mean (SD) 2134.1 (666.7) 2013.8 (644.4) 2073.9 (654.3)
PISA (mm2), mean (SD) 634.5 (629.9) 386.7 (346.2) 510.6 (520.2)
No. of sites with PPD ≥ 5 mm, mean (SD) 60.5 (30.9) 54.3 (27.5) 57.4 (29.2)
% of sites with PPD ≥ 5 mm, mean (SD) 42.2 (19.6) 38.4 (18.1) 40.3 (18.8)
No. of sites with PPD ≤ 4 mm, mean (SD) 83.3 (32.1) 87.1 (30.3) 85.2 (31.1)
% of sites with PPD ≤ 4 mm, mean (SD) 58.0 (19.4) 60.8 (19.1) 59.4 (19.2)
CODS, mean (SD) 4.0 (1.3) 4.1 (1.0) 4.0 (1.2)
OHQoL-UK, mean (SD) 42.7 (6.6) 43.6 (8.7) 43.1 (7.7)
BOP bleeding on probing, CAL clinical attachment level, CODS clinical oral dryness score, eCO expired air carbon monoxide, FTND Fagerstrom Test of Nicotine
Dependence, MGI Modified Gingival Index, MPSS Mood and Physical Symptoms Scale, NCSCT National Centre for Smoking Cessation and Training, OHQoL-UK UK
Oral Health-related Quality of Life measure, PESA periodontal epithelial surface area, PI plaque index, PISA Periodontal Inflamed Surface Area, PPD Pocket probing
depth, SA salivary anabasine, SC salivary cotinine
Holliday et al. Pilot and Feasibility Studies            (2019) 5:74 Page 7 of 14
(SD) number of days using the e-cigarette in the interven-
tion group was 196 (40.2).
Eleven participants used non-recommended e-liquid
brands on at least one time point during the study (see
Additional file 17). They were not obviously different
from the other participants in the intervention group
with regard to age, gender and baseline smoking be-
haviour. However, they made up a high proportion of
the quitters, e.g. five of the six participants (83%) who
achieved RS6. Six participants reported using a different
e-cigarette device (i.e. not the one supplied in the starter
kit) during the study (see Additional file 17).
Process evaluation
Interviews with study participants found that a number
of factors could influence both positive and negative atti-
tudes towards e-cigarettes. In terms of positive attitudes,
these were interactions with existing users (vapers),
health benefits, a perception that vaping was seen as
socially acceptable and the behavioural and sensory
similarities to tobacco smoking. More negative attitudes
were influenced by personal previous e-cigarette ex-
periences, concerns about addiction, concerns relating
to possible health risks of using e-cigarettes and lack of
social acceptability. Interviews also explored the accept-
ability of the e-cigarette starter kit intervention. Overall,
it was perceived to be acceptable with participants, and
they were happy to source and purchase their own
supplies of e-liquid after the initial period. Interviewees
differed in their choice and experience of using different
e-liquid flavours, and there were some instances of tech-
nical difficulties in using the device, particularly in the
first few weeks. Participants have relatively dichotomous
views on flavour preferences, for or against tobacco fla-
vours. Additional file 19 provides further details of these
findings with illustrative quotes.
E-cigarette use in the control group
Two control participants declined to sign the commit-
ment form, and one of these went on to use an e-cigarette
during the study. In total, eight participants in the
control group (20%, 95% CI 11–35%) reported using
an e-cigarette at some point during the study (against
instructions), with one reporting usage at all post-ran-
domisation visits (see Additional file 20).
Methods of smoking cessation (non-e-cigarette)
A variety of smoking cessation techniques were used by
the participants (see Additional file 21). Forty percent of
the control group reported that they made contact with
the Newcastle Stop Smoking service, compared to none
in the intervention group. Four of the eight participants
(50%) who used an e-cigarette in the control group
also reported making contact with the Newcastle Stop
Smoking service.
Biological samples
All the required biological samples were successfully
collected at visit 1 (baseline) and visit 6 (6 months).
Five percent of samples could not be collected at
visit 5 (3 months) because there had been insufficient
healing time following the periodontal therapy (see
Additional file 22).
Smoking and oral health outcome data
Overall, excellent data completeness was achieved
across the outcome measures used in this study for
those attending for follow-up visits. Most measures
achieved 100% completeness at all time points (see
Additional file 22). Overall, those in the intervention
group appeared, descriptively, to have improved
smoking cessation outcomes, although the 95% CIs
were wide (see Table 4). Changes from baseline to
6 months for the oral health outcome measures were
very similar in both groups (see Table 5). However,
results from this pilot RCT should be interpreted cau-
tiously given it was not designed to detect differences
between groups and has not been analysed in a way
that would account for any potential confounding
factors [31, 32].
Table 3 Summary of adverse events (AEs)
Adverse events Control group Intervention group
AEs (n) Participants affected (n) AEs (n) Participants affected (n)
Toothache 4 4 11 9
Dentine hypersensitivity 3 3 3 3
Tooth/teeth loss 5 (6 teeth) 4 5 (9 teeth) 3
Dental/periodontal abscess 2 2 3 3
Mouth ulceration 0 0 2 2
Soreness of intra-oral soft tissues 0 0 3 3
Fractured/carious filling or tooth 3 3 2 2
Other 3 2 6 5
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Definitive study sample size calculation
There are two important outcomes of the e-cigarette
intervention under investigation: smoking abstinence
rates and oral/periodontal health. Therefore, we propose
that the future definitive study should have co-primary
outcomes and be powered accordingly.
In order to detect an 8% difference in 6-month smoking
abstinence rates between intervention arms, with a control
group rate of 7% (90% power, 5% significance level,
two-sided test), 337 participants will be required per arm,
674 in total [33] (see Additional file 23 for further justi-
fications and explanations). Given that any randomised
participants who are lost to follow-up will be included in
the intention to treat (ITT) analysis of smoking abstinence
as smokers at 6months, this sample size has not been
adjusted for attrition. However, the consent rate amongst
those eligible in the pilot RCT was 67% (95% CI 58–75%).
Given that the definitive study will be conducted in
multiple centres and the pilot RCT was conducted in a
single centre, it would be prudent to use the lower bound
of this 95% CI, and on this basis, the future definitive
study would need to approach 1162 potentially eligible
patients in order to consent and randomise 674. Sample
sizes calculated for two potential oral/periodontal health
outcome measures (mean PPD and percentage of sites
with PPD ≥ 5 mm) are less than the sample size calcu-
lated for smoking abstinence (see Additional file 23 for
complete calculations).
The sample size calculations were performed using the
proc power twosamplemeans and twosamplefreq pro-
cedures in SAS version 9.4 of the SAS System for
Windows 7, copyright© 2012 SAS Institute Inc.
Discussion
Main findings
This feasibility study with embedded pilot RCT success-
fully recruited 80 smokers with periodontitis of whom
58 completed the study, yielding a 73% retention rate,
just below the expected 75% rate. Recruitment source
affected several aspects with participants from PIC sites
having the lowest conversion rates (from being identified
to attending and consenting) and retention rates. The
Table 4 Summary of smoking outcome measure data
Outcome Control Intervention
n Baseline rate Rate at follow-up (95% CI) n Baseline rate Rate at follow-up (95% CI)
4-week quitter
(eCO or SC/SA verified)
40 NA 5% (1 to 17%) 40 NA 28% (16 to 43%)
6-month quitter (RS6) 40 NA 5% (1 to 17%) 40 NA 15% (7 to 29%)
n Baseline
mean (SD)
Mean change from baseline
to 6 months (SD; 95% CI)
n Baseline mean (SD) Mean change from baseline
to 6 months (SD; 95% CI)
eCO (ppm) 29 17.1 (10.4) − 5.8 (12.3; − 10.5 to − 1.1) 29 22.0 (12.8) − 12.0 (11.0; − 16.2 to − 7.9)
FTND 29 4.6 (2.5) − 1.6 (2.1; − 2.4 to − 0.8) 29 4.6 (1.6) − 1.9 (2.0; − 2.7 to − 1.2)
MPSS 29 22.8 (7.5) − 2.8 (8.3; − 6.0 to 0.3) 29 21.8 (4.9) − 2.8 (8.8; − 6.1 to 0.6)
SC (ng/ml) 29 277.2 (131.5) − 37.1 (133.4; − 90.0 to 15.7) 29 326.3 (145.5) − 62.2 (132.3; − 112.5 to − 11.8)
SA (ng/ml) 29 0.8 (0.8) 0.5 (2.3; − 0.5 to 1.4) 29 1.2 (1.3) − 0.4 (1.2; − 0.9 to 0.0)
In line with recommendations for smoking cessation trials [4], participants with missing smoking outcome data (e.g. those not attending for review) were
considered as continuing smokers or to have resumed smoking. Hence, the denominator for the 4-week and 6-month quitter outcome is the baseline number of
participants (n = 40). For continuous variables, missing data were not imputed
eCO expired air carbon monoxide, RS6 Russell standard 6-month quitter, FTND Fagerstroms test of nicotine dependence, MPSS Mood and Physical Symptoms
Scale, SC salivary cotinine, SA salivary anabasine, NA not applicable
Table 5 Summary oral health outcome data
Control (n = 29) Intervention (n = 29)
n Baseline
mean (SD)
Mean change from baseline to 6
months (SD; 95% CI)
n Baseline
mean (SD)
Mean change from baseline to 6
months (SD; 95% CI)
Mean PPD (mm), mean (SD; 95% CI) 29 4.0 (0.8) − 0.7 (0.5; − 0.9 to − 0.5) 29 3.8 (0.7) − 0.8 (0.6; − 1.0 to − 0.6)
Percentage of sites with PPD ≥ 5
mm, mean (SD; 95% CI)
29 39.0 (20.8) − 19.3 (13.0; − 24.2 to − 14.3) 29 35.1 (16.2) − 21.5 (13.7; − 26.7 to − 16.3)
% BOP score, mean (SD; 95% CI) 29 25.2 (18.5) − 11.1 (13.5; − 16.3 to − 6.0) 29 17.0 (12.6) − 7.0 (13.6; (− 12.1 to − 1.8)
CODS, mean (SD; 95% CI) 29 3.7 (1.3) − 0.7 (1.6; − 1.3 to − 0.1) 29 3.8 (0.9) − 0.3 (1.3; − 0.8 to 0.2)
OHQoL-UK, mean (SD; 95% CI) 29 43.1 (6.7) 8.2 (15.1; 2.4 to 14.0) 29 43.4 (7.7) 9.6 (13.2; 4.6 to 14.6)
Missing periodontal data due to participant loss to follow-up were not imputed. For teeth that were lost or extracted during the study period, a ‘last observation
carried forward’ approach was used for the periodontal indices where possible
PPD pocket probing depths, BOP bleeding on probing, CODS clinical oral dryness score, OHQoL-UK UK Oral Health-related Quality of Life measure
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vast majority of the participants who did not finish the
study failed to attend a visit and were then uncontact-
able, usually dropping out after the initial periodontal
therapy (which was completed at visit 3). Future trial de-
signs should consider whether the number and duration
of the study visits can be reduced, and the setting of the
research study changed (e.g. more visits in primary care),
in order to minimise participant attrition.
The e-cigarette intervention was well received, with
90% of those in the intervention group using it at the
quit date and over half using it for the duration of the
study. Findings from the process evaluation also suggested
that the e-cigarette intervention was acceptable to parti-
cipants. Several participants chose to diverge from the
recommended brand of e-liquid, and an interesting obser-
vation is that these individuals made up almost all of the
quitters in the intervention group, potentially suggesting
that they were particularly determined to quit smoking
and engaged more broadly with the process to the extent
of exploring the use of other e-liquids. Flexibility and
choice may well be important determinants of quit suc-
cess rates and should be considered when planning future
trials. Furthermore, one in five participants in the control
group used an e-cigarette, against instructions, an impor-
tant variable to consider when designing future research,
indicating the necessity of a pragmatic research design.
Outcome measures were successfully completed in clinic,
but the weekly smoking questionnaire had poor com-
pletion rates. The pilot RCT results suggest that the
e-cigarette intervention may have the potential to improve
smoking cessation outcomes with a greater mean eCO
reduction over the 6 months (control group: 6 ppm;
intervention group: 12 ppm) and increased rates of
eCO-verified continuous 6-month abstinence (control
group: 5%; intervention group: 15%), although this needs
confirming in an appropriately powered definitive trial.
There was almost no difference on average in the change
from baseline to 6months in oral health outcome measures
between the groups although the 95% CIs were wide due
to the small sample sizes and relatively large between-par-
ticipant variation in these measures.
The periodontal treatment was successfully delivered
to all participants, usually over two visits. However, in a
small number of participants (n = 3), due to clinical need
or patient anxiety, the treatment was delivered over
three or four visits. For three participants, we were
unable to collect oral health indices at the 3-month visit
(visit 5) as there had been insufficient healing time
following the completion of the initial treatment to
justify recording the periodontal indices. A proposal for
future research is to drop collection of research data at
the 3-month time point (although a visit at around 3
months may still be needed for supportive periodontal
therapy as part of usual care).
Relationship to previous research
Previous research [34, 35] in this field has rarely pro-
vided in-depth descriptions of participant recruitment,
although 6-month attrition rates are comparable to
those reported in this study.
The eligibility criteria (medical conditions) used in the
current study, although more specifically defined than pre-
vious research [36–38], did not appear to adversely affect
eligibility rates (based on the limited data we have from the
NDH periodontal new patient clinic in which only one out
of 391 patients was ineligible on medical grounds), and
similar criteria could be used in future studies.
The minimum number of teeth required to be eligible
for this study was reduced from 20 to 16 part way
through the study (after 7 months’ recruitment). We
found that, due to the severe nature of periodontitis in
some smokers, many of the potential participants had
suffered from tooth loss previously and had less than 20
teeth remaining. We reviewed the reason for using 20
teeth as a cut-off in previous studies and found this to
be arbitrary. We decided to revise our lower limit to 16
teeth which represents half of the dentition of a normal
adult, giving a fair representation of the disease profile
and enough teeth for the periodontal measures to be
useful and for samples to be collected.
The control group in the current study received SCA as
part of usual care, achieving a 5% quit rate (RS6). This is
similar to the rates discussed in a Cochrane systematic re-
view of brief advice interventions delivered by physicians,
which concluded that the brief advice intervention could
increase 6-month quit rates to 5% from the 3% unassisted
rate [39]. Another Cochrane systematic review focusing
on smoking cessation within the dental setting concluded
that quit rates could be increased to 7% [40]. It was inter-
esting to note that both of the RS6 quitters in the control
group in our study used a self-purchased e-cigarette
(against instructions) as part of their quit attempt. The
intervention group in the current study achieved a 15%
quit rate (RS6) which is similar to previous research
(7.3–12%) [37, 38] and comparable to the longer term
quit rates seen in specialist stop smoking services [41, 42].
In our study, there was contamination of the control
group, with 20% of participants in the control group using
an e-cigarette at some point. Previous studies [37, 38] have
not reported on this, which has likely become more of an
issue with the widespread availability and popularity of
e-cigarettes in recent years. Future research should utilise
a highly pragmatic design, accepting a level of e-cigarette
use by participants in the control group.
There were 56 AEs mainly associated with the sequelae
of severe periodontitis, e.g. toothache, dentine hyper-
sensitivity, tooth loss and abscesses. Direct comparison
with previous research is difficult as AEs have rarely been
reported. Five of the AEs reported in the intervention
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group could have been associated with e-cigarette use or
smoking cessation (mouth ulceration and intra-oral soft
tissue soreness). The Cochrane review on e-cigarettes [9]
found that the most frequently reported adverse events
were mouth and throat irritation.
Strengths and limitations
Strengths
To the best of our knowledge, this is the first RCT of
e-cigarettes in the dental setting or focusing on oral
health. This study was feasibility in scale, with 58 partici-
pants completing it. However, this compares favourably
to the previously conducted prospective studies in this
field, which reported completion numbers of 26
(12-month follow-up) [34] and 63 (6-month follow-up)
[35]. The feasibility study and pilot RCT complied with
reporting guidelines; the CONSORT checklist for pilot
and feasibility studies [13] has been used, and the study
complies with all the relevant checklist items. Similarly,
the interventions provided in this study were reported in
detail using the Template for Intervention Description
and Replication (TiDieR) checklist, enhancing trans-
parency and reproducibility [43]. Our findings will allow
for a well-designed and efficient definitive study in order
to answer a research question evaluating the effective-
ness, cost-effectiveness and safety of an e-cigarette
intervention for smoking cessation delivered alongside
periodontal therapy and if this leads to improved
periodontal outcomes.
Limitations
The contamination rate of the control group (using
e-cigarettes, against instructions) was an important finding
of the current study. On the one hand, this adds to the
reasons why these pilot RCT results should be interpreted
cautiously, but on the other, it is an important feasibility
outcome that will shape the design of a future defini-
tive study.
The current study was conducted in a single specialist
DCRF within a secondary care environment (NDH), in
which the chief investigator and principal investigator
were based. This allowed for dedicated experienced
research teams to conduct high-quality research, but
applicability to primary care may be reduced compared
to a study conducted in a primary care environment.
Future studies should consider this in their design.
Additionally, the SCA was delivered by a single clinician
in this pilot RCT, unlike a future trial which would have
multiple operators.
The control group in the current study appeared to
have more severe periodontitis at baseline than the inter-
vention group. Ideally, the groups should have balanced
disease profiles, and hence, a future definitive study
should stratify for periodontitis severity.
Blinding was not possible for the collection of the
smoking outcome measures, mainly for practical reasons,
e.g. staffing limitations. West et al. [18] discuss the con-
cern that lack of blinding may lead to differential efforts
being devoted to contacting subjects in different treatment
groups, and they recommend that follow-up rates should
be reported by group. We reported detailed follow-up
rates by group and found that equal numbers of parti-
cipants (29 in each group) completed the study. Those
participants lost to follow-up appeared to have higher
eCO and FTND readings and more severe periodontitis. It
is noteworthy that similar studies have also not employed
blinding [37, 44].
A common challenge with all e-cigarette research is
the rapidly moving pace of the field, particularly with
regard to product development and use. The product we
used in our study, although still available for sale at the
end of the trial, had largely been superseded. The rapid
changes in popularity and usage of e-cigarettes also
potentially make the applicability of the findings challen-
ging. In order for the findings of the current study to
remain of optimal relevance, it is important that a defini-
tive study is instigated rapidly.
Implications for future research
Overall, this feasibility study with embedded pilot RCT
demonstrated that the offer of an e-cigarette starter kit
by a dentist to smokers with periodontitis was feasible
and acceptable. Its evaluation within this context was
possible, and there are several design implications for a
future definitive study. These include expected recruit-
ment and retention rates; conducting part of the re-
search in primary care; eligibility criteria in relation to
numbers of teeth; not including willingness to quit as an
inclusion criterion; study design to be highly pragmatic
(broad inclusion criteria, conducted in primary dental
care and the e-cigarette intervention having a range of
flavour choices, including tobacco and non-tobacco
flavours); stratification based on periodontitis severity;
not collecting research data at the 3-month time point;
reducing the number of outcome measures collected;
not using the weekly smoking questionnaire (or collect-
ing such data less frequently); having co-primary out-
comes (smoking abstinence rates and a measure of oral/
periodontal health); and a sample size based upon the
pilot RCT data.
Conclusions
It was feasible and acceptable to provide an e-cigarette
intervention for smoking cessation, for patients with
periodontitis, within the dental setting. The results suggest
that the e-cigarette intervention may improve smoking
quit rates. The findings of this study will inform the design
and sample size of a future definitive study.
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